| 2.58 0.05 (1.98%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.37 | 1-year : | 3.64 |
| Resists | First : | 2.88 | Second : | 3.11 |
| Pivot price | 2.74  |
|||
| Supports | First : | 2.5 | Second : | 2.08 |
| MAs | MA(5) : | 2.6 |
MA(20) : | 2.81 |
| MA(100) : | 3.2 |
MA(250) : | 4.68 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 7.2 |
D(3) : | 7 |
| RSI | RSI(14): 32.8 |
|||
| 52-week | High : | 7.94 | Low : | 2.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAGE ] has closed above bottom band by 23.8%. Bollinger Bands are 36.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.6 - 2.62 | 2.62 - 2.63 |
| Low: | 2.49 - 2.51 | 2.51 - 2.53 |
| Close: | 2.55 - 2.58 | 2.58 - 2.61 |
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Thu, 15 Oct 2026
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 - Business Wire
Mon, 12 Oct 2026
Niagen Bioscience (Nasdaq:NAGE) - Stock Analysis - Simply Wall Street
Tue, 06 Oct 2026
Niagen Bioscience to Present at LD Micro 20th Annual Main Event - Business Wire
Wed, 30 Sep 2026
Niagen Bioscience (NAGE): Can Its NAD+ Business Drive the Next Leg of Growth? - Yahoo Finance
Tue, 29 Sep 2026
Niagen Bioscience: Down 68%, But Still Not Quite A Buy (NASDAQ:NAGE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 79 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 29.4 (%) |
| Held by Institutions | 41.5 (%) |
| Shares Short | 3,870 (K) |
| Shares Short P.Month | 4,160 (K) |
| EPS | 0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.03 |
| Profit Margin | 12.3 % |
| Operating Margin | 2.3 % |
| Return on Assets (ttm) | 5.4 % |
| Return on Equity (ttm) | 21.7 % |
| Qtrly Rev. Growth | -4.4 % |
| Gross Profit (p.s.) | 1.04 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | -75 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | 13.57 |
| PEG Ratio | 0 |
| Price to Book value | 2.48 |
| Price to Sales | 1.58 |
| Price to Cash Flow | 34.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|